Company Filing History:
Years Active: 2025
Title: Innovations by Jeffrey Gau
Introduction
Jeffrey Gau is an accomplished inventor based in San Mateo, California. He has made significant contributions to the field of nucleic acid sequencing, holding 3 patents that showcase his innovative approaches to enhancing imaging systems.
Latest Patents
One of his latest patents is titled "Apparatus and method for extended depth of field." This invention involves a method for extending the depth of field of a nucleic acid sequencer. The method includes optimization steps that are repeated multiple times, comparing the results of light passing through an objective lens and a mask with an ideal result. Any discrepancies found are used to update the mask, which is incorporated into a nucleic acid sequencer that adds fluorescent tags to nucleic acid sites. This advancement allows for improved detection of light emitted from the fluorescent tags, thereby extending the sequencer's depth of field.
Another notable patent is "Intelligent sample tilt adjustment with zones having variable size." This method involves obtaining surface profile data of a sample swath divided into multiple tiles. The surface profile data is used to calculate zones that include adjacent tiles, and based on this data, a detilt or detip value is associated with each zone. This value indicates the necessary adjustments to be made before capturing images, enhancing the accuracy of the imaging system.
Career Highlights
Jeffrey Gau is currently employed at Illumina Corporation, a leading company in the field of genomics. His work focuses on developing innovative solutions that improve the efficiency and accuracy of nucleic acid sequencing technologies.
Collaborations
One of his notable coworkers is Anindita Dutta, with whom he collaborates on various projects aimed at advancing the capabilities of imaging systems in genomic research.
Conclusion
Jeffrey Gau's contributions to the field of nucleic acid sequencing through his innovative patents demonstrate his commitment to enhancing scientific research. His work at Illumina Corporation continues to push the boundaries of technology in genomics.